ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1282

Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study

Swati Arora1, Brad Rovin2 and Tanmayee Bichile3, 1Allegheny Health Network, Pittsburgh, 2The Ohio State University, Columbus, OH, 3Allegheny Health Network, Gibsonia, PA

Meeting: ACR Convergence 2022

Keywords: Infection, Lupus nephritis, pulmonary, Systemic lupus erythematosus (SLE), Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Measures and Measurement of Healthcare Quality Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with autoimmune disorders such as systemic lupus erythematosus (SLE), lupus nephritis (LN) and granulomatosis with polyangiitis (GPA) frequently require treatment with immunosuppressive drugs. These patients are at higher risk of developing opportunistic infections with Pneumocystis jiroveci pneumonia (PJP) when exposed to long term glucocorticoids and cytotoxic medications. Often times, the care of these patients requires a multidisciplinary team where providers may have different approaches to management. The aim of this study is to compare similarities and differences in practice patterns of providers in nephrology and rheumatology with respect to PJP prophylaxis.

Methods: After appropriate IRB approval, we used Survey Monkey™ to survey nephrologists and rheumatologists. Surveys were sent via email to providers based in the USA and internationally. All responses were anonymous and voluntary.

Results: We received 101 survey responses, 50.5% of respondents were rheumatologists and 49.5% were nephrologists. Females comprised 54.5% of the respondents. The majority of respondents, 69.3%, practiced at an academic institution while 21.8% were in private practice. Many providers (33.7%) had been in practice for over 20 years, while 17.8% had been in practice for less than 5 years. The majority of respondents were from North America (USA, Canada), but there were respondents from Europe, South America and Asia. Table 1 highlights the differences in response to survey questions between nephrologists and rheumatologists. With respect to PJP prophylaxis, there was no statistically significant difference in practice patterns among the two groups for patients on prednisone >20mg/d, mycophenolate mofetil (MMF), rituximab and cyclophosphamide (CYC). We did find a statistically significant (p< 0.05) difference in practice patterns among the two specialties with respect to consideration of PJP prophylaxis for patients with GPA (p value 0.02) and lupus nephritis (0.008) with rheumatologists favoring PJP prophylaxis in GPA and nephrologists in LN. There was also a statistically significant difference with comfort of prescribing hydroxychloroquine among these specialties (p value 0.001). Both groups were in favor of improved PJP prophylaxis guidelines.

Conclusion: Our survey study highlights the similarities and differences among nephrology and rheumatology providers with respect to PJP prophylaxis. There is unanimity among nephrologists and rheumatologists to use PJP prophylaxis among patients on immunosuppressive therapies such as prednisone >20mg/d, MMF, CYC, rituximab. However the uniformity of PJP prophylaxis was not observed for disease states like GPA and LN highlighting the need for further studies. There is consensus among nephrologists and rheumatologists for improved PJP prophylaxis guidelines.

Supporting image 1


Disclosures: S. Arora, Aurinia, GlaxoSmithKlein(GSK), Aurinia; B. Rovin, AstraZeneca, Aurinia, Biogen, Genetech, Janssen, Lupus Foundation of America, GlaxoSmithKlein(GSK); T. Bichile, None.

To cite this abstract in AMA style:

Arora S, Rovin B, Bichile T. Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/practice-patterns-for-pneumocystis-jiroveci-pneumonia-pjp-prophylaxis-among-nephrologists-and-rheumatologists-an-international-survey-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/practice-patterns-for-pneumocystis-jiroveci-pneumonia-pjp-prophylaxis-among-nephrologists-and-rheumatologists-an-international-survey-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology